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Abstract: 
Chromosomal microarray (CMA) assesses chromosome copy number variants 
(CNVs) missed by standard karyotyping. The American College of Obstetricians and 
Gynecologists (ACOG) recommends CMA for all patients with fetuses with an 
ultrasound anomaly and suggests that it be made available to all women undergoing 
invasive testing. In order to assess prenatal genetic counselors’ (GCs) practices 
regarding the utilization of CMA we conducted a survey of their current practices, 
attitudes, and perceived barriers. Of the 192 respondents, 183 (95%) have 
incorporated CMA into clinical practice with the majority (64%) believing that the 
benefits of CMA outweigh the harms. However, only half (52%) of the respondents 
agreed that CMA should be offered to all women regardless of indication. The 
respondents who reported feeling that they were experts/comfortable in their 
knowledge of CMA (85%) and were familiar with current clinical guidelines (86%) 
were significantly more likely to offer CMA to all patients undergoing invasive testing, 
patients with fetuses with anomalies, and those referred for advanced maternal age. 
Genetic counselors report not offering CMA to patients due to patient specific 
concerns (51%), such as anxiety or health literacy, financial concerns (39%), 
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difficulty of interpreting results (39%), lack of data (36%), and time constraints 
(22%). Patient specific concerns were the largest reported barrier when GCs chose 
not to offer CMA to patients which, is different than the studies which predate the 
ACOG guidelines that cited financial and ethical concerns as barriers. Our study 
demonstrates that GCs follow established guidelines for use of CMA when specific 
indications are involved but further guidelines are needed regarding use of CMA for 
other common prenatal indications.  Based on this, other professional societies such 
as National Society of Genetic Counselors should consider publishing guidelines on 
prenatal CMA that are specialized to the GCs sphere of practice.      
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Introduction 
Chromosomal microarray analysis (CMA) is a genetic test that can identify 
chromosomal aneuploidy as well as chromosomal microduplications and 
microdeletions, referred to as copy number variants (CNVs). CNVs are often too 
small to be detected by a conventional karyotype, but are implicated as a cause of 
multiple genetic disorders that may manifest as congenital anomalies or a fetal 
demise during pregnancy 1. 
CMA has been used in pediatric and adult genetic clinics for over a decade, 
and the American Academy of Pediatrics recommends CMA as a first-tier test for 
individuals with autism spectrum disorder, developmental delay, unexplained 
intellectual disability, and multiple congenital anomalies 2.  
In 2012 a multi-center prospective trial conducted by the National Institute of 
Child Health and Human Development (NICHD) showed that, in the presence of a 
normal karyotype, approximately 6% of pregnancies with fetal anomalies detected 
on ultrasound, and 1.7% of pregnancies with routine indications, such as advanced 
maternal age, had clinically significant CNVs detected on prenatal CMA 3. 
Subsequent studies showed higher detection rates of CNVs, 6.5% in the presence of 
an abnormal fetal ultrasound, and 8.2% in the presence of fetal demise 1. 
Based on this, the American College of Obstetricians and Gynecologists 
(ACOG), in conjunction with the Society for Maternal and Fetal Medicine (SMFM), 
published a joint statement in 2013 recommending CMA as the first-line test when a 
prenatal ultrasound shows one or more major fetal abnormalities 4. Guidelines also 
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recommend CMA as the preferred genetic test to help identify the cause of fetal 
demise and stillbirth, and that CMA should be made available to any patient 
undergoing diagnostic testing 4. This was later reinforced by the updated 2016 
ACOG and SMFM practice bulletin which further stated that CMA should be a 
primary test, replacing karyotype, for patients with fetal structural abnormalities 5. 
However, more prospective studies are needed to demonstrate the diagnostic utility 
and benefit, as well as cost effectiveness of prenatal microarray in all pregnant 
women. 
One major complication with the technology of prenatal microarray is the 
detection of CNVs of unknown significance, also referred to as variants of uncertain 
significance (VUS), and the difficulty of interpreting VUS results 6. The overall VUS 
rate in prenatal CMA is reported to be 1.5%-1.6% 7, 8. Information regarding CNVs 
that are detected prenatally or in healthy individuals is very limited. In the hopes to 
improve these gaps, several databases, such as ClinVar and DECIPHER, have 
been established to help collect and distribute such information 9, 10. Parental or 
family studies can aid in reclassification of variants given that CNVs inherited from 
an unaffected parent tend to be benign, however, parental blood samples are not 
always available for analysis, and incomplete penetrance cannot be excluded 11. For 
patients undergoing prenatal microarray testing, the uncertainty about the predicted 
clinical phenotype and lack of precise risk estimate associated with VUS, particularly 
in the absence of congenital abnormalities, may increase parental and family anxiety 
and distress, as well as impact decision making regarding the pregnancy 15. 
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Additionally, studies on cost effectiveness of CMA in prenatal diagnosis are 
limited.  Test coverage by insurance companies also varies.  While many insurance 
providers deem CMA to be “medically appropriate and/or necessary” in cases of 
fetal structural abnormalities, many insurance companies still consider CMA to be 
“investigational” or “experimental” and are not routinely covering the testing 
especially in the absence of ultrasound abnormalities or other high risk factors 12-14. 
Appropriate pretest and posttest genetic counseling, with a thorough 
discussion of the benefits and limitations, is warranted for patients undergoing 
prenatal microarray. ACOG recommends that certain points should be shared with 
the patients prior to undergoing CMA and these include, but are not limited to, that 
results may or may not be informative in terms of identifying a known genetic 
condition, conditions detected by CMA may have high variability in clinical 
presentation, may identify consanguinity or non-paternity, and that results may 
identify adult-onset disease 7. 
While discussion and ordering of prenatal CMA can be done by various 
healthcare providers, genetic counselors are a subgroup of health professionals who 
are uniquely trained in counseling regarding the benefits, limitations, and risks 
associated with prenatal screening and testing options. Genetic counselors who 
counsel patients frequently order prenatal tests, interpret and disclose these results, 
and facilitate decision making and coordination of care following the results. Several 
studies have therefore looked at the experiences and attitudes of genetic counselors 
toward prenatal microarray. 
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A 2012 survey of 160 prenatal genetic counselors practicing in North America 
showed that the majority (73%) of respondents found prenatal microarray to be a 
useful tool, and 84% presented it to patients as a prenatal diagnostic option, but only 
69% reported to have ordered a prenatal microarray at least once. Reported 
challenges included financial issues and ethical concerns, as well as the difficulty of 
interpreting uncertain results and explaining these complex results to patients 16. 
Another study of 193 prenatal genetic counselors found that only 59% of counselors 
would be comfortable providing genetic counseling and 43% would be comfortable 
helping a patient make a decision about pregnancy termination in the presence of an 
uncertain microarray result 17.  
The above cited literature regarding the attitudes and practices of genetic 
counselors regarding microarray testing largely predate the ACOG guidelines 
released in December of 2013 4 and all predate the recent 2016 practice bulletin 5.  
The current study aims to evaluate whether prenatal genetic counselors have 
incorporated prenatal microarray into their clinical practice within the framework of 
current guidelines, as well as their current practices regarding test ordering, pretest 
counseling, and informed consent. The study will clarify prenatal genetic counselor 
utilization as well as knowledge, beliefs, and perceived barriers toward 
implementation of prenatal microarray into clinical practice. 
Methods 
This study was approved by the Committee for the Protection of Human 
Subjects at the University of Texas McGovern Medical School at Houston (#HSC-
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MS-16-0520). This was a survey based cross-sectional study of English-speaking, 
board certified or eligible genetic counselors who currently practice prenatal genetic 
counseling and discuss prenatal diagnostic testing options with patients. Participants 
for the study were recruited via an email to the members of the National Society of 
Genetic Counselors (NSGC). Participation was voluntary. Members who agreed to 
participate by providing informed consent were asked to complete an anonymous 
online survey. The incentive for the completion of survey was that the participants 
were given the option of providing their email address in a separate email apart from 
the survey if they wished to enter a drawing for a gift card. 
The survey was created, distributed, and managed using Qualtrics online 
software (Qualtrics, Provo, Utah) approved for use by the University of Texas 
McGovern Medical School at Houston Institutional Review Board. The survey was 
created for the study but did not employ formal or validated measures. There were 
two arms to the survey, Arm A and Arm B, depending on if the participants did not or 
did incorporate CMA into their prenatal practice, respectively. The questions 
consisted of multiple choice, Likert scale, and free responses and were designed to 
assess demographic information, knowledge and beliefs, current practices of 
prenatal genetic counselors in regards to the use of CMA, and perceived barriers. 
The initial email was sent to the NSGC membership August 1, 2016 and a second 
reminder email was sent on September 12, 2016. Data collection was closed 
October 1st and the survey link was deactivated. A full copy of the survey is available 
in the Appendix. 
Data Analysis 
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Descriptive statistics were presented as number (percentage) and mean ± 
SD. Comparison of data generated from the survey questions was evaluated using 
Pearson Chi-square analysis and Fisher exact test. Findings were considered 
statistically significant if the p-value was <0.05 in this study. Data was analyzed 
using STATA software (v.14.1, College Station, TX). 
Results 
At the time our survey was distributed there were 3,189 counselors registered 
as members of NSGC. Of the 252 surveys that were started, a total of 192 
participants completed the entire survey (76%). The open rate was 27.6% for the 
first email and 26.3% for the second email. Per the 2016 professional survey, 43% 
are prenatal counselors that practice in a clinical setting.   
Demographics 
The majority of the participants reported having less than 10 years of total 
genetic counseling (70%) and prenatal specific genetic counseling (73%) 
experience, spending over half of their time counseling patients in a clinical setting 
(81%), and seeing more than 10 patients per week (69%). The greatest number 
reported working at an institution that had 5 or less genetic counselors (73%), in a 
university medical center or academic institution (40%), did not work for an institution 
associated with a laboratory that performs prenatal CMA (74%), and did not work for 
a center that provides fetal intervention (71%). A complete list of participant’s 
demographics is summarized in Table 1. Most genetic counselors surveyed saw 
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more patients with private insurance than Medicaid, state health insurance, and self-
pay (Table 2). 
Overall, the participants’ reported demographic information was 
representative of the results gathered in the National Society of Genetic Counselors 
2016 Professional Status Survey. 
Table 1. Demographics 
Demographics N= 192 Percentage 
Years of genetic counseling experience 
<5 
 
92 48% 
6-10 
 
42 22% 
11-15 
 
21 11% 
16-20 
 
18 9% 
>20 
 
19 10% 
Years of prenatal genetic counseling experience 
<5 105 55% 
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6-10 35 18% 
11-15 21 11% 
16-20 17 9% 
>20 14 7% 
Time spent counseling in the clinical prenatal setting 
1-20% 20 10% 
21-40% 17 9% 
41-60% 25 13% 
61-80% 34 18% 
81-100% 96 50% 
Prenatal patients seen per week 
<5 24 13% 
6-10 35 18% 
11-15 64 33% 
16-20 48 25% 
>20 21 11% 
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Work setting 
University Medical Center/Academic Institution 76 40% 
Private Hospital/Medical Facility 45 23% 
Public Hospital/Medical Facility 37 19% 
Government or Military Hospital/Medical Facility 1 1% 
Private Practice/Office 24 12% 
Commercial Diagnostic Laboratory 5 3% 
Other 4 2% 
Region of practice 
 
Region 1:  
CT, MA, ME, NH, NY, RI, VT, CN, Maritime Provinces 
22 12% 
Region 2:  
DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec 
32 17% 
Region 3:  
AL, FL, GA, KY, LA, MS, NC, SC, TN 
22 11% 
Region 4:  
AR, IA, IL, IN, KS, MI, MN, MO, ND,  
NE, OH, OK, SD, WI, Ontario 
48 25% 
Region 5:  
AZ, CO, MT, NM, TX, UT, WY, 
 Alberta, Manitoba, Saskatchewan 
29 15% 
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Region 6:  
AK, CA, HI, NV, ID, OR, WA, British Columbia 
39 20% 
Number of prenatal genetic counselors at institution 
0 40 21% 
1-5 101 53% 
6-10 28 15% 
11-15 16 8% 
>15 7 4% 
Work in a center that provides fetal intervention 
 
Yes 46 24% 
No 137 71% 
Unsure 9 5% 
Work for a hospital/laboratory/commercial entity that 
performs prenatal CMA 
Yes 47 24% 
No 141 74% 
Unsure 4 2% 
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Figure 1.  
 
Knowledge and Beliefs 
Participants were asked to describe their current level of knowledge regarding 
prenatal CMA, with most reporting they felt they were either an expert and could 
teach others, or that they were comfortable ordering the test without further 
education (n=163, 85%). The majority reported to be current with clinical guidelines 
for the use of prenatal CMA (n=166, 86%). A little over half agreed that CMA should 
be offered to all patients regardless of indication (n=99, 52%) and a larger portion 
agreed that the benefits of CMA in its current form outweighed the harms (n=123, 
64%) (Table 3). 
0
20
40
60
80
100
120
140
160
180
200
Medicaid Private Insurance Other state health
insurance (i.e. CHIP)
Self-Pay
Percentage of Patients Seen with the Following Insurance 
Coverage (n=192): 
0-24% 25-49% 50-74% 75-100%
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Table 2. Knowledge and Beliefs 
Knowledge and Beliefs N= 192 Percentage 
Level of knowledge regarding prenatal microarray 
Expert 
 
53 28% 
Comfortable no need for further education 
 
110 57% 
Comfortable, would like more education 
 
27 14% 
Basic knowledge 
 
1 0.5% 
No knowledge 
 
1 0.5% 
Familiar with current clinical guidelines for prenatal microarray 
Yes 166 86% 
No 3 2% 
Unsure 23 12% 
I believe prenatal microarray should be offered to all women regardless of 
indication 
Agree/Somewhat agree 99 51% 
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Neutral 11 6% 
Disagree/Somewhat disagree 82 43% 
I believe that, in its current form, the benefits of prenatal microarray 
outweigh the harms 
Agree/Somewhat agree 123 64% 
Neutral 38 20% 
Disagree/Somewhat disagree 31 16% 
 
Incorporation into Practice 
Genetic counselors were asked if they had incorporated prenatal CMA into 
their clinical practice by offering it as an option to patients, and the majority reported 
that they have (n=183, 95.3%). Of the 9 participants who have not incorporated CMA 
into their clinical practice (Arm A), when asked if they anticipated that they would 
begin offering the test in the future, 5 were unsure when they would incorporate it 
into use, and 2 reported they would incorporate it within the next 6 months. Only 1 
stated that they did not plan on offering prenatal CMA in their clinical practice.  
For those who have incorporated it into their practice (Arm B), detailed 
questions were asked with the intent of evaluating their current utilization and 
practices. We put forward sampled indications, modeled on ACOG guidelines or 
based on indications genetic counselors might encounter in a clinical setting, and 
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asked participants how frequently they offer prenatal CMA given that specific 
indication by using a Likert scale. Results are summarized in Figure 2. 
Figure 2.  
 
0% 20% 40% 60% 80% 100%
All patient undergoing genetic
counseling
Patient of advanced maternal age
(AMA)
Patients with a positive screening for
fetal aneuploidy
All patients with a non-structural fetal
anomaly
All patients undergoing invasive testing,
regardless of indication
Patients with a desire to know "all
information possible"
Patients presenting with fetal demise or
stillbirth
Patients with a personal or family history
of microdeletion or microduplication
Patients with a positive NIPT for
microdeletion or microduplication
All patients with a structural fetal
anomaly
Frequency Prenatal CMA is Offered Given the Following 
Indication (n=183):
Mostly/Always Half the time Rarely/Never
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The greatest number of participants, 95%, reported that they “mostly” or 
“always” offer CMA to patients with a structural fetal anomaly and 0% reported to 
“never” or “rarely” offering CMA for this indication. Eighty seven percent of the 
participants reported to “mostly” or “always” offer CMA to patients presenting with a 
fetal demise or stillbirth, and 71% reported to “mostly” or “always” offer CMA to their 
patients undergoing invasive testing. The participants that were offering CMA to 
patients undergoing invasive testing were significantly more likely to report feeling 
comfortable in their knowledge of CMA and did not need further education (p=.011). 
Participants who said they “rarely” or “never” offer CMA for fetal demise or 
stillbirth (9%) were more likely to report that lack of data regarding yield and utility 
was influential in not offering the test, and were more likely to disagree that CMA 
should be offered to all patients, although these responses did not show statistical 
significance (p=.435, p=.257). Participants who reported to “rarely” or “never” offer 
CMA to patients undergoing invasive testing (20%) were significantly more likely to 
report that the difficulty of interpreting results was influential in not offering this test 
(p=.009) and were significantly more likely to disagree that CMA should be offered to 
all patients (p<.001). 
In general, the majority of participants reported “mostly” and “always” offering 
prenatal CMA for most of the sample indications. The exceptions were that, 
approximately an equal number of participants reported “rarely” or “never” (45%) and 
“mostly” and “always” (44%) offering CMA in the case of advanced maternal age 
(AMA), and 66% reported “rarely” or “never” offering CMA to all patient undergoing 
prenatal genetic counseling. Those that “mostly” or “always” offer CMA for AMA 
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were significantly more likely to report being current with guidelines (p=.023) and 
report being comfortable with their knowledge of CMA (p=.001). 
Of the participants who are not offering CMA for all patients undergoing 
counseling, this group was significantly more likely to report that patient specific 
concerns influenced this decision (p=.047) as well as difficulty in interpreting results 
(p=.009). Of the participants who are not offering CMA for all patients undergoing 
counseling and for patients who are AMA, this group was significantly more likely to 
disagree that prenatal CMA should be offered to all patients regardless of indication 
(p<.001 and p<.001 respectively). Those who were “never” or “rarely” offering CMA 
for AMA were significantly more likely to report desiring more education regarding 
CMA (p=.001).     
Additionally, of the participants who reported “never” or “rarely” offering CMA 
to patients with non-structural abnormalities, a family history of microdeletion and 
microduplication syndromes, positive screen for aneuploidy, and patients who want 
all information possible, were more likely to say that lack of data plays a 
moderate/high degree of influence when not offering CMA (p=.001; p=.035; p=.004, 
p=.001, respectively). 
Frequency of use of CMA was compared to other demographic information 
provided by the participants, but no other statistically significant trends were 
encountered. 
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Barriers 
Of the 9 genetic counselors who have not incorporated prenatal CMA into 
their practice, 89% (n=8) reported that financial concerns, as well as the possibility of 
receiving uncertain or ambiguous results (89%, n=8), played a moderate to high 
degree of influence, followed by difficulty of interpreting results (78%, n=7). In 
comparison, this group reported that patient specific concerns, such as anxiety or 
health literacy (89%, n=8), and time constraints (78%, n=7) had little influence. Due 
to the small sample size, further statistical analysis could not be performed. 
Several reasons for not offering CMA were also reported by the 183 
participants who offer prenatal CMA, including patient specific concerns (51%), 
financial concerns (37%), difficulty of interpreting results/lack of data (39%), and time 
constraints (22%). For participants who cited financial concerns as the reason for not 
offering CMA to patients, there were no statistically significant differences between 
the types of insurance their patients reportedly had (p=.198, p=.670, p=.868).   
Barriers were compared to other demographic information provided by the 
participants, but no other statistically significant differences were encountered. 
Results are summarized in Figure 3. 
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Figure 3.  
 
Pre-Test and Test Ordering Practices 
 Participants who have incorporated CMA into clinical practice were asked 
how frequently they discussed certain points during pre-test counseling (Figure 4). 
The points that were “mostly” or “always” discussed by the majority of participants 
include: CMA can yield a pathogenic or abnormal result (99%), the severity of the 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Time Constraints/Lack of Support Staff
Financial Concerns
Lack of Data Regarding Yield/Utility
Difficulty of Interpreting Results
Patient Specific Concerns
Factors that Play a Role When Prenatal CMA is not offered 
to the Patient (n=183):
High Degree Moderate Degree Low Degree No Influence
19 
 
phenotype may not be predictable (96%), the results may be a VUS (96%), results 
may have implications for the parents (74%), and results can show incidental 
findings, such as non-paternity (68%). However, approximately half of participants 
reported that they “rarely” or “never” discuss that results may indicated an adult 
onset disorder (48%). Those that do not discuss adult onset disorders tended to 
have less than 10 years of experience, but this was not statistically significant 
(p=.072). This was also compared to other demographic information provided by the 
participants, but no other statistically significant trends were encountered. 
 On average, 55% of participants who have incorporated CMA into their 
practice reported ordering more than 10 prenatal CMAs per year and expanded 
arrays were ordered more often than targeted arrays (64% vs. 33%). Most 
participants (57%) reported ordering SNP arrays more frequently than 
oligonucleotide arrays only (4%) or combination arrays (oligonucleotide with SNP, 
30%). Those participants who ordered SNP arrays most often were less likely to 
work for an entity that performs CMA (p=.001). GCs that work with 5 or less GCs at 
their institution were significantly more likely to order SNP arrays (p=.001) while 
those GCs who have 11+ GCs at their institution were significantly more likely to 
order combination arrays (p=.001). Forty-five percent of participants reported 
“mostly” or “always” ordering CMA in conjunction with a full karyotype, 25% reported 
ordering CMA only with no accompanying karyotype, and 15% reported to ordering 
CMA with a limited or 5 cell karyotype.  
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Approximately half of the participants reported only obtaining a verbal consent 
when consenting patients for CMA (51%) followed by 43% that obtained both verbal 
and written consent. Many participants felt that incorporating CMA into their 
discussion during the session did not alter the length of an average genetic 
counseling session, but that the length varied based on the case specifics or clinical 
indication (55%). Fifteen percent reported that they, or their institution, participated in 
data sharing, such as ClinGen, while 46% did not, and 39% were unsure.  Those 
who reported data sharing were significantly more likely to work for an academic 
institution (p=.046).  Working at a fetal center did not make a GC more likely to 
participate in data sharing (p=.019) and neither did working for an institution that 
performs CMA (p=.001). 
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Figure 4.  
 
 
 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Result may indicate an adult onset
disorder
Result may be an incidental finding
(ex.non-paternity)
Result may have implications for one or
both parents
Cost and Insurance coverage
Result may be abnormal/pathogenic but
not be predictable
Result may be a variant of known
signficance
Result may be abnormal/pathogenic
Frequency of Pre-Test Counseling Discussion Points for CMA 
(n=183):
Most/Always Half the Time Never/Rarely
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Resources 
Participants were asked what resources they use to stay current on 
information regarding prenatal CMA. The majority reported to stay current using the 
guidelines or practice bulletins from professional organizations (n=176) followed by 
information gathered at national or scientific meetings (n=160). The fewest number 
of participants reported using marketing material from commercial laboratories to 
stay current (n=52). In the free response section, several participants stated that 
they utilize the expert knowledge and recommendations of laboratory genetic 
counselors, and that discussions with their colleagues were an important resource. 
Figure 5.  
1
51
135
139
160
176
None of the above
Marketing materials from commercial
laboratories
Peer-reviewed journals
Review articles by experts on the topic
National or scientific meetings
Guidelines or Practice Bulletins from
professional organizations
Resources Used to Stay Current on Information about 
Prenatal Microarray
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Discussion 
This study provides a cross-sectional view of current prenatal genetic 
counselors’ practices and utilization of prenatal CMA, as well as barriers and 
challenges they encounter in North America. This is not the first study to evaluate 
genetic counselors’ utilization, attitudes, and perceived barriers in relation to prenatal 
CMA, but it is the first study since ACOG published their guidelines and 
recommendations for its use in the prenatal setting.  
This study demonstrates that nearly all prenatal genetic counselors surveyed 
have incorporated prenatal CMA into their clinical practice by offering it to their 
patients (95.3%), with most ordering more than 10 arrays per year (55%), and the 
majority feeling very comfortable in their current knowledge of prenatal CMA without 
desiring further education (83.3%). This differs from the 2012 surveys that found 
only 84% of prenatal genetic counselors presented CMA to their patients, and that 
genetic counselors desired more education and resources about prenatal CMA 
testing 16, 17. This increase in utilization of prenatal CMA is likely due to a 
combination of factors, including the availability of guidelines set forth by 
professional organizations, number of discussions and presentations regarding CMA 
at national conferences such as the NSGC’s Annual Education Conference, as well 
as the publication of peer-reviewed studies which further demonstrated the utility of 
CMA in the prenatal setting 2, 3, 8, 18-21. 
This study also shows that the vast majority of genetic counselors surveyed 
(95%) are offering prenatal CMA to patient’s whose fetus has been identified with a 
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structural anomaly, 87% are offering CMA in the presence of stillbirth or fetal 
demise, and 71% are offering CMA to all patients undergoing invasive testing 
demonstrating that overall prenatal genetic counselors are practicing in concordance 
with ACOG guidelines regarding utilization of CMA 7. 
Genetic counselors, however, were much less likely to offer CMA to all 
patients undergoing prenatal genetic counseling and those who are seen for routine 
indications, such as AMA. ACOG guidelines do not explicitly “recommend” but state 
that CMA “should be considered” for all women undergoing invasive testing, leaving 
it up to the provider to decide who to offer it to 7.  Most of the counselors who were 
offering CMA to patients cited patient specific concerns, such as anxiety and health 
literacy, as well as difficulty interpreting results as barriers to why they are not 
offering CMA in these situations.  Although patient specific concerns was a newly 
reported barrier to offering prenatal CMA, the barrier of difficulty of interpreting 
results has been repeatedly reported in previously published studies 16.  Given the 
likelihood of finding a clinically significant CNV in pregnancies with common 
indications, like positive serum screening or AMA (1.3-1.7%), is similar to the 
likelihood of finding a VUS on CMA (1.5-1.6%), and evidence that VUS results 
significantly increase parental and family anxiety and distress3, 15, 22, this is not an 
unreasonable concern. More studies are needed; however, to explore how genetic 
counselors evaluate factors such as patient anxiety during a genetic counseling 
session when they are deciding whether to offer CMA. 
Recommendations on the type of pre- and posttest counseling patients 
should receive prior to ordering a CMA have previously been recommended 6 and 
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reiterated by ACOG 7. In our study, genetic counselors reported frequently reviewing 
the recommended pre-test counseling discussion points with patients (Figure 4) 
such as the types of results that CMA may yield. They also reported discussing 
financial concerns, such as insurance coverage and cost of testing, before testing is 
ordered. However, only about half of the genetic counselors reported discussing 
those results may indicate an adult onset disorder, despite ACOG guidelines. It is 
unclear from our study why this is so, but it may be due to the fact that at least 33% 
of counselors reported primarily ordering targeted arrays, which may decrease the 
chance of receiving these types of results. Further research into why certain results 
are not discussed as regularly with patients as other types of results, and the genetic 
counselors reasons for not doing so, would provide better insight into whether this 
decision is based mainly on the type of array ordered, the time constraints of the 
session, if it is a personal preference of the genetic counselor, or if there is a 
combination of factors effecting this decision. 
Unlike preivously published concerns 16, financial issues did not play as large 
of a role when counselors did not offer CMA as it did in the past.  Increasing 
coverage of CMA testing by commercial insurance providers and the continually 
decreasing cost of CMA testing may be contributing factors.  Insurance companies 
often conform to the recommendations of professional organizations, such as 
ACOG, and begin to cover new services when such recommendations are 
established 6. When published medical policies from a few major insurance carriers 
were reviewed at the time this study was performed, many policies largely mirrored 
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the language of the ACOG guidelines giving further evidence that insurance 
companies often utilize national guidelines when deciding patient coverage. 
Overall, our study demonstrates that prenatal genetic counselors, despite 
practicing in many different settings and with varying years of experience, are 
utilizing CMA within the context of clinical guidelines. Genetic counselors reportedly 
follow pre-test counselling guidelines, believe that CMA is a useful test, and feel 
comfortable with their knowledge of CMA. Despite this, over half still believe that 
CMA should not be offered to all patients, regardless of indication, confirming the 
fact that more studies are still needed on the utility of CMA for all pregnant women. 
  We did not observe a need for further education on CMA technology, as the 
majority of counselors felt comfortable in their knowledge.  However, the consistent 
barrier to ordering CMA appeared to be patient specific concerns, such as anxiety 
and health literacy.  Therefore, further studies and education on CMA should 
continue to focus on providing more information on those factors which influence 
patient anxiety, such as receiving a VUS, and encourage more data sharing to 
further minimize the risk of uncertain results. Current guidelines and previous studies 
have alleviated earlier genetic counselors’ concerns on the utility and yield of 
prenatal CMA for certain clinical indications, and have decreased certain barriers to 
ordering CMA such as ethical concerns, but there is still a lack of data and 
guidelines for how prenatal microarray should be utilized for other indications 
commonly seen by prenatal genetic counselors.  
At this time there are no studies that focus on the patient specific concerns 
experienced by patients undergoing a discussion of prenatal microarray testing. A 
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study looking at these patients concerns with an emphasis at teasing out what 
exactly are the specific underlying causes of those concerns could provide more 
information on how medical professions, specifically genetic counselors, could better 
address these concerns during their conversations with patients. Professional 
societies, particularly NSGC, may consider publishing guidelines that focus, not 
necessarily on when it should be clinically indication, but more so on evaluating and 
addressing patient specific concerns related to prenatal CMA. Established guidelines 
from NSGC would allow GCs access to guidelines specialized to their sphere of 
practice and further address some of the concerns noted in this study. 
Study Limitations  
This survey was distributed via email to the entire NSGC membership listserv 
and may represent a skewed population. Genetic counselors who either are not 
members of NSGC, or those who declined to receive student surveys, had their 
practices, experiences, and voices excluded. With any study, there is the inherit 
selection bias that those who take part may have an affinity for this subject matter or 
have very strong opinions regarding CMA, which may make them more likely to 
respond to the survey than those who find this subject less interesting. A large 
portion of genetic counselors who responded to this survey (24%) reported working 
at a center that offered fetal intervention, which is a higher number than expected 
based on the number of fetal centers nationally, and may see a disproportionally 
higher number of patients with ultrasound anomalies than those with standard 
indications.   
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Although our survey was distributed early in the fall semester, before the 
usual onslaught of student surveys were released upon the NSGC membership, 
there is the risk that we limited our participation because of survey fatigue 
experienced by NSGC members. Our survey was also designed to have forced 
responses, in other words, the participant could not move forward in the survey 
before answering the current question. We had many partially completed surveys, 
which were not included in our study, which may have been caused by this 
mandatory response setting and fatigue from answering a longer survey. 
It was also impossible to calculate a response rate for our study. Per the 2016 
professional survey, 43% are prenatal counselors that practice in a clinical setting.  
Based on how this survey was distributed, however, it is not possible to calculate 
how many NSGC members meet our eligibility criteria or how many received and/or 
opened the survey. This is because the email was sent to the entire NSGC 
membership, but there is not accurate data kept on who within the membership 
identify specifically as a clinical prenatal counselor. Because of this we only have the 
email open rate, which is also skewed by the fact that genetic counselors of other 
specialties, students, and other NSGC members opened the email. Additionally, the 
study was not based on validated measures and may have caused misinterpretation 
by the participants when answering the questions. 
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Appendix 
The Integration of Prenatal Microarray: A Survey of Current Genetic Counseling 
Practices and Barriers 
 
1. To assess prenatal genetic counselors’ practices regarding the utilization of 
prenatal microarray 
2. To assess prenatal genetic counselors’ perceived barriers regarding prenatal 
microarray 
 
Members:  Nevena Krstic, Blair Stevens, Sarah Jane Noblin, Dr. Ramesha Papanna, 
Dr. David Rodriguez 
 
Do you consent to moving forward with the survey? 
 a. Yes, I wish to participate 
 b. No, I do not wish to participate 
 
1. Do you provide prenatal genetic counseling? 
a. Yes 
b. No 
 
If No Selected, Then Skip to End of Survey 
 
2. Do you discuss prenatal diagnostic testing options, such as chorionic villus 
sampling (CVS) and amniocentesis, with patients? 
a. Yes 
b. No 
 
If No Selected, Then Skip to End of Survey 
 
3. Currently, how much of your time is spent counseling patients in the clinical 
prenatal setting? 
a. 0% 
b. 1-20% 
c. 21-40% 
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d. 41-60% 
e. 61-80% 
f. 81-100% 
 
If 0% Selected, Then Skip to End of Survey 
 
4. Approximately how many prenatal patients do you see per week, including both 
new and follow-up patients? 
a. <5    
b. 6-10 
c. 11-15 
d. 16-20 
e. >20 
 
5. How many years of total genetic counseling experience do you have? 
a. <5  
b. 6-10  
c. 11-15  
d. 16-20  
e. >20  
 
6. How many years have you worked in the clinical prenatal setting? 
a. <5  
b. 6-10  
c. 11-15  
d. 16-20 
e. >20  
 
7. What region do you currently practice in? 
a. Region 1: CT, MA, ME, NH, NY, RI, VT, CN, Maritime Provinces  
b. Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec 
c. Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN 
d. Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, 
Ontario 
e. Region 5:  AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, 
Saskatchewan 
f. Region 6: AK, CA, HI, NV, ID, OR, WA, British Columbia 
 
8. What type of setting do you currently work in? 
a. University Medical Center/Academic Institution 
b. Private Hospital/Medical Facility 
c. Public Hospital/Medical Facility 
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d. Government or Military Hospital/Medical Facility 
e. Private Practice/Office 
f. Commercial Diagnostic Laboratory 
g. Other (Please Specify):__________ 
 
9. In your primary work setting, roughly what percentages of your patients are in 
the following groups? (Please approximate; groups may not sum up to 100%) 
 
 0% 1-9% 10-24% 25-49% 50-74% 75-
100% 
Private Insurance 
 
      
Medicaid 
 
      
Other State Health 
Insurance (ie. CHIP) 
      
Self Pay 
 
      
Other (please specify): 
 
      
 
 
10.  How many prenatal genetic counselors, other than yourself, currently work in 
your institution? 
a. None, I am the only prenatal genetic counselor in my institution 
b. 1-5 
c. 6-10 
d. 11-15 
e. >15 
 
11. Do you currently work in a center that provides fetal interventions such as in-
utero spina bifida   repair, twin-to twin transfusion laser surgery, etc.?   
a. Yes 
b. No 
c. Unsure 
 
12. Are you directly involved in counseling patients who are evaluated for and/or 
are candidates for fetal intervention? 
a. Yes, I am directly involved 
b. No, I am not directly involved 
c. No, I am not directly involved but I refer patients who are evaluated for 
fetal intervention 
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13. What statement best describes your current level of knowledge regarding 
prenatal microarray? 
a. I am an expert and can teach others about it 
b. I am comfortable ordering the test without further education  
c. I am comfortable ordering the test, but desire more education 
d. I know the basics of the test but am not comfortable ordering it 
e. I do not know anything about the test 
 
14. Are you familiar with current clinical guidelines for use of prenatal microarray? 
a. Yes 
b. No 
c. Unsure 
 
15. Do you work for a hospital, laboratory, or commercial entity that also performs 
prenatal microarray? 
a.    Yes 
b. No 
c. Unsure 
 
       16. Please indicate to what extent you agree or disagree with the following 
statements: 
 
 Disagree Somewhat 
Disagree 
Neither 
Agree nor 
Disagree 
Somewhat 
Agree 
Agree 
I believe 
prenatal 
microarray 
should be 
offered to all 
women, 
regardless of 
indication or 
pursuit of 
invasive testing 
o  o  o  o  o  
I believe that in 
its current form, 
the benefits of 
o  o  o  o  o  
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prenatal 
microarray 
outweigh the 
harms 
 
        17. Have you incorporated prenatal microarray into your clinical practice by 
offering it as an option?  
 a. Yes 
 b. No 
 
If yes, skip to question 20 
If no continue to next question 
 
18. When do you anticipate that you or your institution will begin offering prenatal 
microarray in your clinical practice? 
a. I do not plan to offer prenatal microarray in my clinical practice 
b. Within the next 6 months 
c. Within the next year 
d.    More than 1 year from now 
e.    Unsure 
 
19. To what degree do the following factors play a role in why prenatal microarray 
has not been offered in your clinical practice?  
 
 
 No 
Influence 
Low Degree Moderate 
Degree 
High 
Degree 
Financial Concerns 
(Cost, insurance 
coverage, etc.) 
o  o  o  o  
Possibility of 
uncertain/ambiguous 
results 
o  o  o  o  
Difficulty of interpreting 
results (ie.VUS, 
incidental findings) 
o  o  o  o  
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Lack of knowledge or 
data regarding 
yield/utility 
o  o  o  o  
Patient specific 
concerns (health 
literacy, anxiety, etc.) 
o  o  o  o  
Time constraints/lack of 
support staff 
o  o  o  o  
Other (please specify): 
 
o  o  o  o  
 
 
 
End of Survey 
 
20. Please select the frequency with which you offer prenatal microarray given 
the following indication: 
 
 Never Rarely About half 
the time 
Most of 
the time 
Always 
All patients undergoing 
prenatal genetic 
counseling 
 
o  o  o  o  o  
Patients undergoing 
invasive testing, 
regardless of indication 
o  o  o  o  o  
Patients with structural 
fetal anomalies  
(ie. cardiac; renal) 
o  o  o  o  o  
Patients with non-
structural fetal 
anomalies  
(ie. soft signs; IUGR; 
polyhydramnios) 
o  o  o  o  o  
Patients of advanced 
maternal age (AMA) 
 
o  o  o  o  o  
Patients with a positive 
screening for fetal 
aneuploidy  
o  o  o  o  o  
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(ie. NIPT or serum 
screening) 
Patients with a positive 
NIPT for 
microdeletion/duplication  
o  o  o  o  o  
Patients with a personal 
or family history of 
microdeletion/duplication 
o  o  o  o  o  
Patients presenting with 
fetal demise/stillbirth 
o  o  o  o  o  
Patients with a desire to 
know “all information 
possible” 
o  o  o  o  o  
Other (please specify): 
 
 
o  o  o  o  o  
 
 
21. To what degree do the following factors play a role when prenatal microarray is 
not offered to the patient?  
 
 
 No Influence Low Degree Moderate 
Degree 
High 
Degree 
Financial Concerns 
(Cost, insurance 
coverage, etc.) 
o  o  o  o  
Difficulty of interpreting 
results (ie. VUS, 
incidental findings) 
o  o  o  o  
Lack of data regarding 
yield/utility 
o  o  o  o  
Patient specific 
concerns (health 
literacy, anxiety, etc.) 
o  o  o  o  
Time constraints/lack of 
support staff 
o  o  o  o  
Other (please specify): 
 
o  o  o  o  
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      22. Approximately how many times have you ordered prenatal microarray in the   
last year? 
a. 0 
b. 1-5  
c. 6-10 
d. >10 
 
       23. Please select the frequency with which you order the following: 
 
 Never Rarely About half 
the time 
Most of 
the time 
Always 
Targeted array 
 
o  o  o  o  o  
Expanded array 
 
o  o  o  o  o  
 
       24. Please select the frequency with which you order the following: 
 
 Never Rarely About half 
the time 
Most of 
the time 
Always 
Array only 
 
o  o  o  o  o  
Array with full karyotype 
 
o  o  o  o  o  
Array with limited/5 cell 
count karyotype 
 
o  o  o  o  o  
 
      25. What type of array do you most frequently order? 
 a. Oligonucleotide array 
 b. SNP array 
 c. Combination (oligo and SNP) array 
 d. Unsure 
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       26. At present, how is informed consent for prenatal microarray obtained in your 
clinic? 
a. Verbal consent 
b. Written consent 
c. Verbal and written consent 
d. Other (please specify):___________ 
 
27. Has the amount of time it takes to complete a genetic counseling session 
changed with implementation of prenatal microarray into your practice? 
a. Yes, it has become longer 
b. Yes, it has become shorter 
c. No change 
d. Varies based on case/clinical situation 
e. Unsure 
 
      28. How frequently do you discuss the following during pre-test counseling for 
prenatal microarray? 
 
 Never Rarely About half 
the time 
Most of 
the time 
Always 
Result may be 
abnormal/pathogenic  
o  o  o  o  o  
Result may be 
abnormal/pathogenic 
but the nature or 
severity of the 
defects/disease may 
not be predictable 
o  o  o  o  o  
Result may indicate an 
adult onset disorder 
o  o  o  o  o  
Result may have 
implications for one or 
both of the parents 
o  o  o  o  o  
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Result may be a variant 
of unknown significance 
(VUS/VOUS) 
o  o  o  o  o  
Result may be an 
incidental finding (non-
paternity, 
consanguinity, incest, 
etc.) 
o  o  o  o  o  
Cost and insurance 
coverage 
 
o  o  o  o  o  
 
       29. Do you or your institution participate in data sharing (ie. ClinGen)? 
 a. Yes 
 b. No 
 c. Unsure 
 
30. What resources do you use to stay current on information about prenatal 
microarray?                  Select all that apply 
__Guidelines or Practice Bulletins from Professional Organizations 
__Peer-reviewed journals 
__Review articles by experts on the topic 
__National or scientific meetings 
__Marketing material from commercial laboratories 
__Other (please specify):_____________ 
__None of the above 
 
 
Thank you for taking part in this survey. If you wish to take part in the drawing for 2 
$50 Amazon gift cards please email Leslie.Durham@uth.tmc.edu with the subject 
line microarray drawing. Your survey responses will not be linked to your email. 
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